ACADIA PHARMACEUTICALS INC

ACAD · Nasdaq · SIC 2834: Pharmaceutical Preparations · Market Cap: $3.8B · 798 employees
278
SEC Filings
$29.11
Close 2026-08-28
1
Transcripts
798
Employees

Business Summary

ACADIA Pharmaceuticals is a biopharmaceutical company focused on neurological and rare diseases. It commercializes NUPLAZID (pimavanserin), the only FDA-approved drug for hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE (trofinetide), the only FDA-approved treatment for Rett syndrome. Combined net product sales totaled $1,071.5 million in 2025. The company also has a pipeline including remlifanserin for Alzheimer's disease psychosis and Lewy Body Dementia Psychosis, ACP-211 for MDD, ACP-711 for essential tremor, and ACP-271 for tardive dyskinesia and Huntington's disease.

Latest Stock Quote

ACAD 2026-08-28 $29.11 O:$29.51 H:$29.725 L:$29.02 Vol:1.5M VWAP:$29.1906
origin leaf: null

Next Earnings

expected 2026-12-11

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionACADdiscussed Regulation
topic_mentionACADdiscussed Automotive
metricACAD total revenuereported $1.07 Billion
guidanceACADguided Guidance NUPLAZID Net Sales $692 Million
guidanceACADguided FY 2025 GAAP Financial Highlights FY25 Results FY26 GAAP Guidance NUPLAZID Net Sales $692 Million

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-262025-12-310001193125-26-072519EDGAR89K words
2025-02-272024-12-310000950170-25-029253EDGAR81K words
2024-02-282023-12-310000950170-24-021473EDGAR81K words
2023-02-282022-12-310000950170-23-004757EDGAR—
2022-03-012021-12-310000950170-22-002392EDGAR—
2021-02-252020-12-310001564590-21-008372EDGAR—
2020-02-272019-12-310001564590-20-006889EDGAR—
2019-02-272018-12-310001564590-19-004596EDGAR—
2018-02-272017-12-310001564590-18-003526EDGAR—
2017-02-282016-12-310001564590-17-002866EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2026-08-052026-06-300001193125-26-333243EDGAR51K words
2025-11-062025-09-300001193125-25-267453EDGAR49K words
2025-08-072025-06-300000950170-25-104295EDGAR49K words
2025-05-082025-03-310000950170-25-066231EDGAR45K words
2024-11-072024-09-300000950170-24-122513EDGAR50K words
2024-08-072024-06-300000950170-24-092163EDGAR49K words
2024-05-092024-03-310000950170-24-056077EDGAR47K words
2023-11-032023-09-300000950170-23-058436EDGAR—
2023-08-032023-06-300000950170-23-037458EDGAR—
2023-05-082023-03-310000950170-23-018927EDGAR—
2022-11-032022-09-300000950170-22-021438EDGAR—
2022-08-092022-06-300000950170-22-015642EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-09-240001193125-26-401157EDGAR2K words
2026-09-110001193125-26-389400EDGAR22K words
2026-08-040001193125-26-332858EDGAR3K words
2026-03-050001193125-26-092213EDGAR1K words
2026-02-250001193125-26-071674EDGAR4K words
2026-01-130001193125-26-011706EDGAR1K words
2025-11-050001193125-25-266959EDGAR3K words
2025-11-030001193125-25-262610EDGAR1K words
2025-08-060000950170-25-104092EDGAR3K words
2025-06-100001193125-25-138452EDGAR1K words

278 total filings indexed. 246 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Earnings Transcripts

Call DateQuarterTitle
— ACAD Earnings Call Transcript

Access full transcripts via API (JSON) — includes speakers, key metrics, competitive mentions, and origin provenance chain.

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACIU — AC Immune SA ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

neurological-diseases rare-diseases parkinson's-disease-psychosis rett-syndrome alzheimer's-disease-psychosis lewy-body-dementia-psychosis major-depressive-disorder essential-tremor tardive-dyskinesia huntington's-disease

Company Identity

CIK0001070494
TickerACAD
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE
HeadquartersSan Diego, California
Websitehttps://www.acadia.com
Listed2004-05-27

Get More Data

This is a static snapshot. For live, structured JSON with cryptographic provenance chain:

MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp

JSON Profile Stock Quote Origin Record
Origin Provenance
page leaf: 6143d44c65111391bf70a23c9419fff1a6c8bbde07e51241c6eef90cde628f92
parent: 10c2dbfabe3738e003f111e2b000d124b5a6e0dc923c8d0339ec2a2199376231
content hash: 38def1ac0af28c0314ebea2ef9db11e6d554be0b126842ac6c1e1e6e11ff1ef0
signed: 2026-09-27T19:00:05.270Z
sources: 23 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf

Try it — paste this into your AI:

Look up ACAD using the MCP server at origin.rootz.global/mcp. What do their latest SEC filings show?

Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.

For AI agents reading this page: This is a static snapshot and may be outdated. For live data on ACAD, use the Origin MCP server or REST API.
MCP install: claude mcp add origin --transport http https://origin.rootz.global/mcp
API: GET https://origin.rootz.global/api/company/ACAD (~200 tokens, structured JSON with cryptographic provenance)
Tools: origin_company, origin_profile, origin_timeline, origin_filings, origin_quote, origin_transcripts, origin_search, origin_person, origin_skill
Discovery: /.well-known/ai | /llms.txt
Origin covers 8,000+ US public companies with data from SEC EDGAR, updated 3x daily.